GLP-1 Receptor Agonists: A Breakthrough in Reducing Atherosclerosis and Cardiovascular Risk Beyond Diabetes and Obesity
GLP-1 receptor agonists significantly reduce atherosclerosis progression, inflammatory biomarkers, and cardiovascular events independent of glycaemic control and obesity status, evidenced by robust preclinical and large-scale clinical data.
Section: CardiologyJul 22, 2026
